CD19 and neoplasm: In addition, when patients experienced CD19‐negative relapse after CD19 CAR‐T therapy, CAR‐T cells targeting CD22 or BAFF‐R can eliminate the relapsed tumor that was resistant to CD19 CAR‐T cells.[22, 23] Therefore, finding new CAR targets for T‐ALL would be useful in the clinic.